Sugi Predict

Sugi Predict / Compounds / SCHEMBL135908

SCHEMBL135908

SCHEMBL135908

CCOC(=O)Cc1ccc(O)c(Br)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 11/20 0.51
▸ HDAC6 Q9UBN7 9/20 0.51
▸ HDAC3 O15379 2/20 0.51
▸ HDAC2 Q92769 2/20 0.51
▸ HDAC4 P56524 1/20 0.51
▸ HDAC7 Q8WUI4 1/20 0.51
▸ HDAC10 Q969S8 1/20 0.51
▸ HDAC11 Q96DB2 1/20 0.51
▸ HDAC8 Q9BY41 1/20 0.51
▸ HDAC9 Q9UKV0 1/20 0.51
▸ HDAC5 Q9UQL6 1/20 0.51
▸ YWHAG P61981 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ GFER P55789 1/20 0.46
▸ ESR1 P03372 1/20 0.46
▸ CYP4Z1 Q86W10 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ NFKB1 P19838 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12900615 0.85 CYP4Z1 (0.46) YWHAGALDH1A1CYP4Z1NPC1PKM
SCHEMBL4140693 0.85 YWHAG (0.68) YWHAGALDH1A1GAAGFERCYP4Z1
SCHEMBL31741653 0.85 YWHAG (0.68) YWHAGALDH1A1GAAGFERCYP4Z1
SCHEMBL3746070 0.84 CYP4F2 (0.58) HDAC1HDAC6HDAC3HDAC2HDAC4
SCHEMBL24793087 0.84 CYP4Z1 (0.44) HDAC6HDAC4YWHAGALDH1A1CYP4Z1
SCHEMBL3649411 0.83 ESR1 (0.53) YWHAGALDH1A1GAAGFERESR1
SCHEMBL1303490 0.83 ALDH1A1 (0.66) HDAC1HDAC6HDAC3HDAC2HDAC4
SCHEMBL30027871 0.83 ALDH1A1 (0.66) HDAC1HDAC6HDAC3HDAC2HDAC4
SCHEMBL2293094 0.83 KDM4E (0.53) YWHAGALDH1A1CYP4Z1NPC1PKM
SCHEMBL2429225 0.83 ALDH1A1 (0.45) ALDH1A1GAAGFERCYP4Z1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158039-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2023-05-25 — — US disclosed
US-20210236508-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2021-08-05 — — US disclosed
CN-106986872-B Bromodomain inhibitors 艾伯维公司 2020-04-21 — — CN disclosed
US-20180296566-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2018-10-18 — — US disclosed
EP-2970193-B1 PYRROLE AMIDE INHIBITORS ABBVIE INC (US) 2018-07-25 — — EP disclosed
EP-2797918-B1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2017-11-29 — — EP disclosed
EP-2794563-B1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2017-02-22 — — EP disclosed
US-9493411-B2 Pyrrole-3-carboxamide bromodomain inhibitors ABBVIE INC. (US) 2016-11-15 — — US disclosed
US-20160143916-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2016-05-26 — — US disclosed
US-9296741-B2 Bromodomain inhibitors ABBVIE INC. (US) 2016-03-29 — — US disclosed
US-7388111-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2008-06-17 — — US disclosed
US-7388111-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2008-06-17 — — US disclosed
WO-2007045573-A1 PHENYL-ACETAMIDE NNRT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-04-26 — — WO disclosed
WO-2007045573-A1 PHENYL-ACETAMIDE NNRT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-04-26 — — WO disclosed
US-20070088053-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2007-04-19 — — US disclosed
US-20070088053-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2007-04-19 — — US disclosed
US-20070088053-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2007-04-19 — — US disclosed
EP-1095932-B1 PHENOXYACETIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME KISSEI PHARMACEUTICAL (JP) 2004-05-19 — — EP disclosed
US-6538152-B1 Obesity, hyperglycemia, urinary incontinence, intestinal or biliary calculi hypermotility, pollakiuria and depression treatment KISSEI PHARMACEUTICAL CO., LTD. (JP) 2003-03-25 — — US disclosed
EP-1095932-A1 PHENOXYACETIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME Kissei Pharmaceutical Co., Ltd. (JP) 2001-05-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180296566-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 HDAC1 15/4885HDAC6 308/4885HDAC3 131/4885
US-20070088053-A1 Non-nucleoside reverse transcriptase inhibitors SAMHD1, QTRT1, RTF1 HDAC1 213/4885HDAC6 1350/4885HDAC3 1253/4885
US-20230158039-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 HDAC1 15/4885HDAC6 308/4885HDAC3 131/4885
US-20160143916-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 HDAC1 15/4885HDAC6 308/4885HDAC3 131/4885
US-20210236508-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 HDAC1 15/4885HDAC6 308/4885HDAC3 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.